医药板块本周震荡分化，资金持续加仓，关注恒生创新药ETF(159316)等产品布局机会

Group 1 - The Hang Seng Innovation Drug Index fell by 2.4% this week, while the CSI Hong Kong Pharmaceutical and Health Comprehensive Index decreased by 2.1%. The CSI Innovation Drug Industry Index and the CSI Biotechnology Theme Index both saw a slight decline of 0.1%. In contrast, the CSI 300 Pharmaceutical and Health Index rose by 0.4% [1] - Continuous capital inflow was observed, with the Hang Seng Innovation Drug ETF (159316) attracting a total of 150 million yuan over the first four trading days of the week, and further net subscriptions were recorded today [1] - The National Medical Insurance Drug List for 2025 and the first version of the Commercial Health Insurance Innovative Drug List (2025) will be released on December 7, marking the 8th adjustment since the establishment of the National Medical Insurance Bureau. A total of 114 new drugs will be added, including 50 Class 1 innovative drugs, covering key areas such as tumors, chronic diseases, mental illnesses, rare diseases, and pediatric medications [1] Group 2 - The CSI Hong Kong Pharmaceutical and Health Comprehensive Index consists of 50 stocks related to medical devices, biopharmaceuticals, chemical drugs, and other healthcare sectors, focusing on leading companies in the healthcare industry [3] - The CSI Innovation Drug Industry Index includes up to 50 stocks primarily engaged in innovative drug research and development, also focusing on leading companies in the healthcare sector [3] - The CSI Biotechnology Theme Index is composed of up to 50 stocks involved in gene diagnostics, biopharmaceuticals, blood products, and other human biotechnology, targeting leading firms in the healthcare industry [3] Group 3 - The historical performance of various indices shows that the Hang Seng Innovation Drug Index has a year-to-date increase of 78.2%, while the CSI Hong Kong Pharmaceutical and Health Comprehensive Index has risen by 72.3%. The CSI Innovation Drug Industry Index has increased by 24.4%, and the CSI Biotechnology Theme Index has seen a rise of 13.9% [6] - Over the past year, the Hang Seng Innovation Drug Index has gained 75.1%, and the CSI Hong Kong Pharmaceutical and Health Comprehensive Index has increased by 68.6%. The CSI Innovation Drug Industry Index has risen by 17.8%, while the CSI Biotechnology Theme Index has seen an 8.3% increase [6] - The rolling price-to-earnings (P/E) ratio for the Hang Seng Innovation Drug Index is closely related to the stability of earnings, making it suitable for industries less affected by economic cycles [9]